Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Receivables (2018 - 2025)

Sunshine Biopharma's Change in Receivables history spans 9 years, with the latest figure at -$41293.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 104.06% year-over-year to -$41293.0; the TTM value through Dec 2025 reached $116173.0, down 95.03%, while the annual FY2025 figure was $116173.0, 95.03% down from the prior year.
  • Change in Receivables reached -$41293.0 in Q4 2025 per SBFM's latest filing, down from $649850.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.8 million in Q2 2024 to a low of -$986986.0 in Q3 2024.
  • Average Change in Receivables over 5 years is $198826.5, with a median of $3899.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: surged 3166200.0% in 2023, then plummeted 1658.68% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $6669.0 in 2021, then soared by 7881.14% to $532262.0 in 2022, then decreased by 10.63% to $475659.0 in 2023, then skyrocketed by 113.81% to $1.0 million in 2024, then plummeted by 104.06% to -$41293.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Change in Receivables are -$41293.0 (Q4 2025), $649850.0 (Q3 2025), and -$65711.0 (Q2 2025).